BI's Spiriva Gets Advisory Panel Nod For COPD Exacerbations Despite Statistical Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee finds clinical trial safety results more compelling than meta-analysis, and is undeterred by the lack of statistical significance in the study's primary endpoints.
You may also be interested in...
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.
Spiriva Safety Debate Pits Clinical Study Results Against Meta-Analysis
FDA also asks advisory panel to assess mixed efficacy results for BI's drug to reduce exacerbation of chronic obstructive pulmonary disease.